The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal ...

Nasal polyps are growths that result from inflamed mucous membranes in the sinuses and nasal passages. They can extend to the opening of the nostrils or even down to the throat area and can block the ...

Small nasal polyps can be harmless, but if a nasal polyp blocks the sinuses or airway, it can lead to infections, difficulty ...

Opens in a new tab or window The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps to include adolescents as well ...

Nasal polyps are soft growths that can occur on the inside of the nasal canal or sinuses. Small nasal polyps can be harmless, but if a nasal polyp blocks the sinuses or airway, it can lead to ...

Dr. Albritton is a resident physician and Dr. Kingdom is Assistant Professor in the Department of Otolaryngology at Emory University School of Medicine, Atlanta, Ga. Albritton FD, Kingdom TT.

Albritton FD, Kingdom TT. Cystic Fibrosis and Nasal Polyposis. MedGenMed 2(1), 2000 [formerly published in Medscape Pulmonary Medicine eJournal 4(1), 2000]. Available at: https://www.medscape.com ...

Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNPCurrent treatment ...

REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.

The safety profile of Dupixent in adolescents with moderate-to-severe asthma contributed to the FDA's decision.

In a recent study investigators established that extended dupilumab therapy-up to three years-is highly effective in the ...